April 2024 in “BMB Reports” This study used Cisd2 knockout mice models and found that these mice display premature aging characteristics and an increase in dysfunctional neutrophils, suggesting Cisd2's role in calcium homeostasis and neutrophil function via interactions with Calnexin and SERCA.
May 2024 in “Biochemical pharmacology” This study found that targeting CISD1 with the compound NL-1 reduced mitochondrial dysfunction and reactive oxygen species accumulation, protecting against cisplatin-induced hearing loss in cell models and mice, without affecting cisplatin's cancer-fighting effectiveness.
May 2026 in “JID Innovations” This study found a significant overlap between gene expression signatures of alopecia areata and certain chronic inflammatory skin disorders, suggesting shared biological processes may drive their co-occurrence and providing a foundation for future research into distinct comorbid subtypes.
May 2026 in “Journal of Human Immunity” In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.
In this case report, a 7-month-old boy with Netherton syndrome experienced significant improvement in symptoms, including reduced pruritus and increased hair growth, through a combination of intravenous immunoglobulin and dupilumab treatment, which also decreased high serum IgE levels and food-specific IgE antibodies.